about
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignColicin import into E. coli cells: a model system for insights into the import mechanisms of bacteriocinsMonoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope GlycoproteinIdentification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 BindingHuman combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virusIdentification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmissionAnalysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolutionNaturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralizationCharacterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virusTagged polymerase chain reaction subtractive hybridization for the enrichment of phage display random peptide libraries.Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.Non-ionic detergents facilitate non-specific binding of M13 bacteriophage to polystyrene surfaces.Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new hostCloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins.B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins.The role of neutralizing antibodies in hepatitis C virus infection.The role of humoral innate immunity in hepatitis C virus infection.The past, present and future of neutralizing antibodies for hepatitis C virus.Human lectins and their roles in viral infections.A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.The P body protein LSm1 contributes to stimulation of hepatitis C virus translation, but not replication, by microRNA-122High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge.Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets.Flexible and rapid construction of viral chimeras applied to hepatitis C virus.Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals.Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection.Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes.Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?
P50
Q26801759-750D8248-E55A-4319-819A-0401595523ABQ26996759-388A31BB-A9A0-4D4C-8B99-6BA5A719058CQ27470798-848C1973-D57D-4D98-91C6-ACAB84A8707CQ27477468-B23DDE2A-4986-4F29-8D6D-EE88B412366DQ27481388-A0B1F4D4-638D-40B0-BC70-091C843711DCQ27666330-E7E52CD8-0927-45F9-8C85-1DDC5C3E2FF4Q27684354-393135E6-F314-4EB8-8F5A-47223CA4D176Q28659586-511B928C-BE5A-424B-961F-BF0E160BC31EQ28731355-1D01F634-6251-4953-BD86-C4FA063F889EQ29619744-40BAD095-48AF-45CB-8143-1C5D741A0E4CQ31153580-AE338492-B5A3-40C9-9662-748BD1FA0649Q33234572-9AF4055C-11BC-442F-897F-F5125CF9AF29Q34683447-528200F8-E0A5-4918-8315-AAE1F5569D6CQ35076885-718C6457-1F73-4898-B765-60E2D664C015Q35619646-F3026030-AD0D-4BB5-84CA-A4B23D601C83Q36363966-49C18B80-681C-4183-BD54-3B58249CDC45Q36821900-C32C0FDA-7BFD-4C24-A03E-8F5E3F94FAADQ37623529-666EC823-A513-4065-A17F-93F45DB202BAQ37952157-42F39E87-52C1-4B87-B8DF-1313857F9B70Q37987129-9D0AEBEB-6B15-4651-81B0-77737071D657Q38192357-9DE51BB6-732D-40D5-B961-7019BC7FA117Q38340871-387AAEB6-F744-4CD8-953D-0ABA9B85E2AAQ38809451-F897118F-2ED3-4C9E-ABB2-79CE4484E765Q38971183-287C23A9-B97D-4621-8816-06D05E34A461Q39076532-82D81183-8EA8-4F47-B8F1-B50928F01386Q39483634-E1E7461C-047C-4FB6-ACFB-30C9454E41B5Q40098163-1CD7D804-C0D9-41DE-AFA3-31A796F6C56EQ40162274-F27DB1B9-F749-47F3-A6CC-27C561045453Q40249390-DB0B6479-6A89-401F-B145-66DA36C90AB7Q40385442-B5B8E60E-14C8-41E8-BCF0-630BB3A0203DQ40688888-CD4CC33E-FA29-472F-8DB0-15F6D8C3D4C2Q40757862-6CE8D213-F421-412F-AA81-3845DC9D5C04Q41619358-11B3FC6B-6227-4673-A259-09808B6EC07EQ42024261-AD28774B-AB46-4CE0-8A98-B69750F9D8F9Q42217086-FC916F88-84DE-4AEB-84D3-92F510F5E181Q42993203-F8215B62-969E-4A03-AD3F-E89DCB2BC75EQ43035409-FC410581-2E2B-4235-8779-4B7824BDAB70Q43047439-42F04057-417E-4D42-966B-CF3D1EBB9C3EQ43048336-DCB04CE1-E5EA-490D-88CF-1BB62DBAA22FQ57203281-DAA7FB6C-DF22-4C32-A467-F50C4B50BCF7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexander W. Tarr
@ast
Alexander W. Tarr
@en
Alexander W. Tarr
@es
Alexander W. Tarr
@nl
type
label
Alexander W. Tarr
@ast
Alexander W. Tarr
@en
Alexander W. Tarr
@es
Alexander W. Tarr
@nl
prefLabel
Alexander W. Tarr
@ast
Alexander W. Tarr
@en
Alexander W. Tarr
@es
Alexander W. Tarr
@nl
P1053
B-7953-2008
P106
P1153
8615905000
P21
P31
P3829
P3835
alexander-tarr
P496
0000-0003-1009-0823